BioSpace News Archive

FDA

AstraZeneca Celebrates a First as FDA Approves Farxiga for Chronic Kidney Disease

The regulatory nod marks the first time the FDA approved an SGLT2 inhibitor for the treatment of CKD regardless of diabetes status.

May 3, 2021
·
2 min read
·
Alex Keown
Business

Relay Therapeutics Appoints Key Leadership Members Following Acquisition

Clinical-stage precision medicine company Relay Therapeutics has brought two new senior level management team members into the fold, including Tara O’Meara and Charles Ferté.

May 3, 2021
·
3 min read
·
Brandon May
Drug Development

A Whole New Era Begins as Roivant and Montes Archimedes Merge in Cash-Rich SPAC

Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC). Once the deal is closed, outstanding shares and warrants of MAAC will be traded for newly issued shares and warrants of the company.

May 3, 2021
·
3 min read
·
Mark Terry
Business

Astellas Pulls the Plug on R&D Partnership with Cytokinetics

One year after Astellas and California-based Cytokinetics extended an agreement to develop Skeletal Sarcomere Activators, the Japanese pharma company is walking away from the deal.

May 3, 2021
·
2 min read
·
Alex Keown
Six Dementia Patients Received Controversial Gene Therapy Injection in Mexico, BioVia Says

If actually administered to these patients, this could represent the first recorded attempt to manage dementia that uses an injectable gene therapy technique.

May 3, 2021
·
3 min read
·
Brandon May
Drug Development

New Hope for Sickle Cell Disease Patients as FDA Approves Chiesi’s Ferriprox

The U.S. FDA approved Chiesi Global Rare Diseases’ Ferriprox for treatment of transfusional iron overload caused by sickle cell disease (SCD) or other anemias in adults and children ages three years and older. This approval expands the use of the drug for patients with SCD or other anemias.

May 3, 2021
·
3 min read
·
Mark Terry
Drug Development

The Seven Stages of Alzheimer’s Disease Explained

There are seven stages of Alzheimer’s disease, and understanding each stage is a useful aid. This article will help you understand each stage properly.

May 3, 2021
·
5 min read
·
Lorenzo Soliman
Business

Already on Fast Track, Aceragen Launches with $35 Million and Farber Disease Drug

Grabbing a fast-tracked novel enzyme replacement therapy for a rare pediatric disease, new biopharma Aceragen launched with $35 million in hand for product financing.

May 3, 2021
·
2 min read
·
Kate Goodwin
Biotech Beach

BIOLASE Urges Stockholders To Vote “FOR&" ALL Proposals At Upcoming Annual Meeting

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today sent the following letter to stockholders regarding the upcoming 2021 annual meeting of stockholders scheduled to be held on May 26, 2021.

May 3, 2021
·
5 min read
Business

Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors

Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of Elizabeth Grammer, Esq., to its board of directors

May 3, 2021
·
2 min read